Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations
A Prospective, Multicenter, Randomized Controlled, Open Label, Non-Inferiority Study Comparing the Efficacy and Safety of the VA Regimen (Venetoclax Combined With Azacitidine) With the "3+7" Regimen in the Treatment of Newly Diagnosed AML Patients With NPM1 or IDH1/IDH2 Mutations
This prospective, multicenter, randomized, open-label, non-inferiority clinical study aims to compare the efficacy and safety of VA regimen (venetoclax combined with azacitidine) versus conventional "3+7" chemotherapy regimen in adult patients aged 18 to 65 years with newly diagnosed acute myeloid leukemia (AML) carrying NPM1, IDH1 or IDH2 gene mutations.
The primary goal of this trial is to check whether the VA treatment can reach a non-inferior composite complete remission rate at the end of the induction treatment cycle, which is the key primary endpoint of this research. Several secondary clinical outcomes will also be evaluated in this study, including the rate of minimal residual disease (MRD) negativity after remission, duration of remission, 1-year event-free survival rate and 1-year overall survival rate of enrolled patients. In addition, the safety and treatment-related side effects occurring during the whole induction treatment phase will be systematically collected and compared between two groups as another important secondary assessment.
Eligible enrolled participants will be randomly split into two study groups: patients in experimental group will receive venetoclax plus azacitidine (VA regimen), while patients in control group will receive standard "3+7" induction chemotherapy following conventional clinical protocol. All subjects will complete regular disease assessment, laboratory examinations and scheduled follow-up visits as required by trial design during treatment and post-treatment observation period.
Researchers will collect and analyze all above clinical outcome data from all participants, to verify the non-inferior efficacy and relative safety of VA regimen for this specific subtype of newly diagnosed AML patients.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Yang Shen, MD
- 电话号码:+86-021-64370045
- 邮箱:sy_clinicaltrial@163.com
学习地点
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200025
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
-
接触:
- Yang Shen, MD
- 电话号码:+86-021-64370045
- 邮箱:sy_clinicaltrial@163.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥ 65 years old ≥ 18 years old;
- Diagnosed as acute myeloid leukemia (non APL) (diagnostic criteria refer to the 2022 ELN classification system);
- Initial diagnosis accompanied by NPM1 mutations (A, B, D types and rare types are all acceptable) and/or IDH1/IDH2 mutations;
- Have not received any other induction therapy before (except hydroxyurea);
- Physical fitness status score (ECOG PS) 0-3;
Having sufficient organ function, defined as follows:
- Liver function: serum total bilirubin ≤ 3 x upper limit of normal range (ULN), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 3 x ULN, unless considered to be caused by leukemia;
- Renal function: endogenous creatinine clearance rate ≥ 30ml/min;
- Heart function: NYHA classification ≤ 2 points;
- Participants must have the ability to understand and be willing to participate in this study, and sign an informed consent form.
Exclusion Criteria:
- Acute promyelocytic leukemia;
- Merge extramedullary infiltration such as central nervous system leukemia;
- Have a clear history of CMML or MDS, and later progress to AML; Or have a history of malignant tumors;
- There is uncontrolled active infection (including bacterial, fungal, or viral infections);
- Pregnant or lactating women;
- Researchers determine that participants are not suitable to participate in this experiment
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Venetoclax plus Azacitidine (VA regimen)
|
Venetoclax,oral targeted anti-BCL-2 agent and Azacitidine,hypomethylating agent, given via injection for experimental VA arm only
|
|
有源比较器:"3+7" induction chemotherapy
Standard 3+7 induction chemotherapy (Cytarabine continuous infusion for 7 days plus Anthracycline intravenous infusion for 3 days) following routine clinical induction regimen for AML.
|
Cytarabine,continuous intravenous infusion for total 7 days and Daunorubicin,Intravenous anthracycline chemotherapy administered for 3 days,in standard 3+7 induction regimen
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Composite complete remission rate at the end of induction cycle
大体时间:At the end of 1-2 induction treatment cycles (each cycle is 28 days)
|
At the end of 1-2 induction treatment cycles (each cycle is 28 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Composite Complete Remission
大体时间:At the end of 1-2 induction treatment cycles (each cycle is 28 days)
|
At the end of 1-2 induction treatment cycles (each cycle is 28 days)
|
|
|
Minimal residual disease (MRD) negative rate after remission
大体时间:At the end of induction cycle (each cycle is 28 days)
|
At the end of induction cycle (each cycle is 28 days)
|
|
|
Duration of Response (DoR)
大体时间:From date of confirmed complete response (CR) until documented disease relapse or death from any cause, assessed up to 24 months after randomization
|
From date of confirmed complete response (CR) until documented disease relapse or death from any cause, assessed up to 24 months after randomization
|
|
|
1-year Event-Free Survival (EFS) rate
大体时间:From date of randomization until first documented treatment failure, relapse, or death from any cause, assessed up to 24 months after randomization; 1-year rate calculated at 12 months post-randomization
|
From date of randomization until first documented treatment failure, relapse, or death from any cause, assessed up to 24 months after randomization; 1-year rate calculated at 12 months post-randomization
|
|
|
1-year Overall Survival (OS) rate
大体时间:From date of randomization until death from any cause, assessed up to 24 months after randomization; 1-year rate calculated at 12 months post-randomization
|
From date of randomization until death from any cause, assessed up to 24 months after randomization; 1-year rate calculated at 12 months post-randomization
|
|
|
1-year recurrence free survival rate
大体时间:From date of randomization until first confirmed disease recurrence or death from any cause, assessed up to 24 months after randomization; the 1-year rate will be calculated at the 12-month timepoint after randomization
|
From date of randomization until first confirmed disease recurrence or death from any cause, assessed up to 24 months after randomization; the 1-year rate will be calculated at the 12-month timepoint after randomization
|
|
|
Safety profile during induction therapy
大体时间:From initiation of induction therapy through the end of the induction treatment period,assessed up to 8 weeks after randomization
|
Evaluate the incidence of grade 3 and grade 4 adverse events classified per CTCAE Version 5.0, the duration of severe adverse events, type, frequency and management of all treatment-emergent adverse events occurring during the induction treatment phase.
|
From initiation of induction therapy through the end of the induction treatment period,assessed up to 8 weeks after randomization
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
Correlation between baseline AML gene mutation status detected by next-generation sequencing and anti-leukemic efficacy endpoints (complete remission rate, MRD-negative rate, 1-year recurrence-free survival rate) in VA regimen arm
大体时间:From date of randomization up to 24 months after randomization, biomarker-efficacy correlation analysis will be performed using clinical data collected within the first 12 months post randomization
|
From date of randomization up to 24 months after randomization, biomarker-efficacy correlation analysis will be performed using clinical data collected within the first 12 months post randomization
|
|
Hospitalization duration during induction therapy
大体时间:From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
|
Transfusion volume during induction therapy
大体时间:From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
|
Medical cost during induction therapy
大体时间:From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
From the date of induction therapy initiation through completion of the first induction cycle (each cycle is 28 days)
|
合作者和调查者
赞助
调查人员
- 首席研究员:Yang Shen, MD、Ruijin Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- NPM1/IDH-AML01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.